DE68912781D1 - Verfahren und zusammensetzungen für die behandlung und zur verhütung von septischen schock. - Google Patents

Verfahren und zusammensetzungen für die behandlung und zur verhütung von septischen schock.

Info

Publication number
DE68912781D1
DE68912781D1 DE89908957T DE68912781T DE68912781D1 DE 68912781 D1 DE68912781 D1 DE 68912781D1 DE 89908957 T DE89908957 T DE 89908957T DE 68912781 T DE68912781 T DE 68912781T DE 68912781 D1 DE68912781 D1 DE 68912781D1
Authority
DE
Germany
Prior art keywords
compositions
treating
methods
septic shock
preventing septic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE89908957T
Other languages
English (en)
Other versions
DE68912781T2 (de
Inventor
Michael Palladino
Stephen Sherwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE68912781D1 publication Critical patent/DE68912781D1/de
Publication of DE68912781T2 publication Critical patent/DE68912781T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68912781T 1988-07-28 1989-07-21 Verfahren und zusammensetzungen für die behandlung und zur verhütung von septischen schock. Expired - Lifetime DE68912781T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22550288A 1988-07-28 1988-07-28
US07/371,484 US5055447A (en) 1988-07-28 1989-06-27 Method and compositions for the treatment and prevention of septic shock
PCT/US1989/003162 WO1990000903A1 (en) 1988-07-28 1989-07-21 Method and compositions for the treatment and prevention of septic shock

Publications (2)

Publication Number Publication Date
DE68912781D1 true DE68912781D1 (de) 1994-03-10
DE68912781T2 DE68912781T2 (de) 1994-07-14

Family

ID=26919658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912781T Expired - Lifetime DE68912781T2 (de) 1988-07-28 1989-07-21 Verfahren und zusammensetzungen für die behandlung und zur verhütung von septischen schock.

Country Status (7)

Country Link
US (1) US5055447A (de)
EP (1) EP0428573B1 (de)
JP (1) JPH04500068A (de)
AU (1) AU628371B2 (de)
CA (1) CA1336680C (de)
DE (1) DE68912781T2 (de)
WO (1) WO1990000903A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529982A (en) * 1985-08-06 1996-06-25 Celtrix Pharmaceuticals, Inc. Inducing granulocyte production or B cell production in peripheral blood by TGF-β
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
EP0480389A1 (de) * 1990-10-12 1992-04-15 Hoechst Aktiengesellschaft Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2121473C (en) * 1991-10-15 2001-05-01 Michael Mullarkey Methods and compositions for treating allergic reactions
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
CA2156721C (en) * 1993-03-16 1999-06-01 Thomas B. Okarma Removal of selected factors from whole blood or its components
US5437861A (en) * 1993-03-16 1995-08-01 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome
US7189834B2 (en) * 1993-05-11 2007-03-13 Marshall William E Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
TW252045B (de) * 1993-10-07 1995-07-21 Allan L Goldstein
AU7393094A (en) * 1994-04-05 1995-10-23 President And Fellows Of Harvard College Transforming growth factor-beta inhibits inducible nitric oxyde synthase gene transcription
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5660826A (en) * 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5734399A (en) * 1995-07-11 1998-03-31 Hewlett-Packard Company Particle tolerant inkjet printhead architecture
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
EP2311485A1 (de) * 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 stimuliert Wundheilung
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6309054B1 (en) 1998-10-23 2001-10-30 Hewlett-Packard Company Pillars in a printhead
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US20070003508A1 (en) 2005-07-01 2007-01-04 Wooley Richard E Methods and compositions for promoting wound healing
US20040151765A1 (en) * 2001-09-18 2004-08-05 Ritchie Branson W. Methods and compositions for wound management
US20040208842A1 (en) * 2001-09-18 2004-10-21 Ritchie Branson W. Antimicrobial cleansing compositions and methods of use
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US6682481B2 (en) * 2002-06-07 2004-01-27 Board Of Regents, The University Of Texas System Resuscitation from shock
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US20070185202A1 (en) * 2004-03-03 2007-08-09 University Of Georgia Research Foundation, Inc. Methods and compositions for ophthalmic treatment of fungal and bacterial infections
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EA201390156A1 (ru) * 2010-07-23 2014-01-30 Бакстер Интернэшнл Инк. ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
KR20140130159A (ko) * 2012-02-10 2014-11-07 재패닉 코포레이션 비 인간 줄기세포의 배양 상등액을 원료로 하는 화장품 또는 피부 재생 촉진제, 및 단백질의 이온 도입 방법
US11214821B2 (en) * 2016-07-18 2022-01-04 Vision Diagnostics, Inc. Reagents and methods of use with automated analyzers for obtaining a specific gravity index for urine
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
US4806652A (en) * 1988-01-27 1989-02-21 Pioneer Hi-Bred International, Inc. Inbred corn line PHR25

Also Published As

Publication number Publication date
AU628371B2 (en) 1992-09-17
WO1990000903A1 (en) 1990-02-08
EP0428573A1 (de) 1991-05-29
DE68912781T2 (de) 1994-07-14
CA1336680C (en) 1995-08-15
EP0428573B1 (de) 1994-01-26
AU4032989A (en) 1990-02-19
US5055447A (en) 1991-10-08
JPH04500068A (ja) 1992-01-09

Similar Documents

Publication Publication Date Title
DE68912781D1 (de) Verfahren und zusammensetzungen für die behandlung und zur verhütung von septischen schock.
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE3485800T2 (de) Verfahren zur behandlung grosser objekte.
DE3874460D1 (de) Verfahren und vorrichtung zur behandlung von schlaemmen.
DE3581642D1 (de) Antimikrobielle antistatische siloxanzusammensetzungen und verfahren zur behandlung von materialien.
DE69019690T2 (de) Verfahren zur Filtrierung und Reinigung von Wasser.
DE69111446D1 (de) Zusammensetzung und verfahren für die wasserreinigung.
DE3582531D1 (de) Verfahren zur behandlung von metalloberflaechen.
DE3853602D1 (de) Modifiziertes Polysilazan und Verfahren zu seiner Herstellung.
DE69103152D1 (de) Zusammensetzung und verfahren zur chromatierung von metallen.
DE68913456D1 (de) Verfahren zur Behandlung von Stahlblech.
DE3581703D1 (de) Verfahren und vorrichtung zur biologischen behandlung von wasser, insbesondere zur denitrifikation von rohwasser zur trinkwasseraufbereitung.
DE3670145D1 (de) Verfahren zur behandlung von abfall.
DE58902128D1 (de) Verfahren zur behandlung von klaerschlamm.
DE3765137D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE3871238D1 (de) Verfahren zur koproduktion von anilinen und oxamiden.
DE69006509D1 (de) Verfahren zur behandlung von häuten.
DE68913995T2 (de) Zusammensetzung zur behandlung progressiver myopie.
DE68907914T2 (de) Verfahren zur behandlung von brandwunden.
DE3579072D1 (de) Vorrichtung zur behandlung von schrammen.
ATE100718T1 (de) Verfahren und zusammensetzungen fuer die behandlung und zur verhuetung von septischen schock.
DE69011065T2 (de) Verfahren zur Behandlung von Nickel-Magnesium-Silikaterzen.
DE68906651D1 (de) Zusammensetzung und verfahren zur behandlung von metalloberflaechen.
DE69005430T2 (de) Metallscavenger und Verfahren für die Abwasserbehandlung.
ATA21789A (de) Verfahren zur behandlung von abfallstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition